Hospital
Prime Healthcare Services - Montclair, LLC
Prime Healthcare Services - Montclair, LLC was paid $11.26M by Medicaid between Jan 2018 and Dec 2024, across 158 billing codes. Its largest line is 0450, Emergency room services — 25% of everything it billed.
33Billing provider infoPRIME HEALTHCARE SERVICES - MONTCLAIR, LLC
MONTCLAIR, CA 91763
MONTCLAIR, CA 91763
33aNPI1992721161assigned 07/14/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$11.26M
24GClaims473,403
24DCodes billed158
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#167 of 410
Median peer was paid$6.90M
This provider vs. median1.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DOAN, CHRISTOPHER controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 54,904 | $1.17M | |
| 2019 | 66,655 | $1.42M | |
| 2020 | 53,506 | $1.29M | |
| 2021 | 66,231 | $1.62M | |
| 2022 | 77,569 | $1.88M | |
| 2023 | 79,031 | $2.01M | |
| 2024incomplete | 75,507 | $1.88M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 25% | 61,568 | 54,810 | $2.77M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 25,461 | 22,901 | $1.50M |
| 70450 | Computed tomography, head or brain; without contrast material | 4.4% | 3,267 | 3,176 | $501K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.4% | 8,532 | 7,889 | $494K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.4% | 3,562 | 3,455 | $383K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.4% | 17,367 | 15,833 | $382K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 3.0% | 9,308 | 8,975 | $336K |
| Z7502 | 2.7% | 8,240 | 8,131 | $309K | |
| 80053 | Comprehensive metabolic panel | 2.5% | 17,496 | 16,124 | $284K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.4% | 10,357 | 9,640 | $267K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.2% | 24,005 | 21,838 | $250K |
| 99499 | 1.9% | 2,917 | 2,529 | $217K |
146 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.8% | 2,539 | $205K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 1.6% | 1,451 | $181K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 6,481 | $163K |
| 0762 | 1.4% | 943 | $163K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.3% | 707 | $148K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 2,146 | $148K |
| 71045 | Radiologic examination, chest; single view | 1.3% | 12,073 | $147K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 6,638 | $120K |
| 81025 | 1.1% | 17,624 | $119K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 10,627 | $87K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,462 | $86K |
| 99070 | <1% | 23,178 | $85K | |
| 83690 | <1% | 8,776 | $84K | |
| 99199 | Unlisted special service, procedure or report | <1% | 1,847 | $80K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,394 | $80K |
| 84484 | <1% | 6,264 | $78K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,276 | $68K |
| J3490 | Unclassified drugs | <1% | 14,317 | $59K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,585 | $56K |
| 81002 | <1% | 13,131 | $55K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,763 | $53K |
| 83880 | <1% | 2,275 | $53K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,329 | $49K |
| 81001 | <1% | 9,118 | $46K | |
| 99285 | Emergency room visit (most serious) | <1% | 315 | $46K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 892 | $42K |
| 73610 | <1% | 1,512 | $41K | |
| 99284 | Emergency room visit (serious) | <1% | 490 | $36K |
| 73630 | <1% | 1,398 | $35K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 16,785 | $34K |
| 84702 | <1% | 2,074 | $33K | |
| 0370 | <1% | 257 | $32K | |
| 73130 | <1% | 1,127 | $30K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 1,108 | $30K |
| 90715 | <1% | 911 | $29K | |
| 87040 | <1% | 2,272 | $29K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 994 | $27K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,001 | $25K |
| 80076 | <1% | 1,930 | $24K | |
| 83605 | <1% | 1,759 | $23K | |
| Z9725 | <1% | 778 | $23K | |
| 73110 | <1% | 840 | $23K | |
| G0378 | Hospital observation service, per hour | <1% | 352 | $23K |
| 73030 | <1% | 885 | $23K | |
| 80305 | <1% | 2,074 | $23K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 394 | $22K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 344 | $21K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,839 | $21K |
| 74018 | <1% | 1,136 | $20K | |
| A4217 | Sterile water/saline, 500 ml | <1% | 3,122 | $20K |
| 87070 | <1% | 1,580 | $19K | |
| 82948 | <1% | 2,401 | $19K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 837 | $17K |
| 87081 | <1% | 2,073 | $17K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 686 | $16K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 80 | $15K |
| 87420 | <1% | 1,109 | $15K | |
| 85730 | <1% | 2,081 | $14K | |
| 0250 | <1% | 2,596 | $13K | |
| 85610 | <1% | 2,430 | $12K | |
| 0270 | <1% | 3,131 | $12K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 561 | $12K |
| 86901 | <1% | 2,074 | $11K | |
| 73564 | <1% | 355 | $11K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 453 | $10K |
| 73562 | <1% | 406 | $10K | |
| 85379 | <1% | 635 | $9K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 3,740 | $9K |
| 0710 | <1% | 353 | $9K | |
| 87186 | <1% | 760 | $9K | |
| 29125 | <1% | 839 | $8K | |
| 99221 | <1% | 45 | $8K | |
| 86900 | <1% | 2,023 | $8K | |
| 93971 | <1% | 64 | $7K | |
| 83735 | <1% | 788 | $6K | |
| 0259 | <1% | 1,116 | $6K | |
| Z7610 | <1% | 377 | $6K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,266 | $5K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,873 | $5K |
| 82150 | <1% | 553 | $5K | |
| 86886 | <1% | 636 | $5K | |
| 76801 | <1% | 92 | $5K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,452 | $5K |
| Q0092 | Set-up portable x-ray equipment | <1% | 541 | $5K |
| 73080 | <1% | 163 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,084 | $5K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 94 | $4K |
| 88313 | <1% | 244 | $4K | |
| 73140 | <1% | 218 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,131 | $4K |
| 93976 | <1% | 14 | $4K | |
| 82550 | <1% | 409 | $3K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 150 | $3K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 44 | $3K |
| 88342 | <1% | 64 | $3K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,192 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,404 | $3K |
| 12001 | <1% | 171 | $2K | |
| 0011A | <1% | 67 | $2K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 12 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 999 | $2K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 54 | $2K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 242 | $2K |
| 71101 | <1% | 39 | $2K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 767 | $1K |
| 88312 | <1% | 90 | $1K | |
| 0012A | <1% | 32 | $1K | |
| 72100 | <1% | 38 | $1K | |
| 29515 | <1% | 105 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,641 | $1K |
| 10060 | <1% | 62 | $999.20 | |
| 73090 | <1% | 48 | $990.46 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 102 | $960.04 |
| 12011 | <1% | 25 | $954.31 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 1,199 | $907.42 |
| 76830 | Ultrasound, transvaginal | <1% | 14 | $905.52 |
| 59025 | Fetal non-stress test | <1% | 60 | $764.14 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,078 | $755.84 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 41 | $738.89 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 12 | $570.36 |
| 74022 | <1% | 12 | $515.75 | |
| 12002 | <1% | 26 | $455.29 | |
| 43235 | <1% | 27 | $441.75 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 24 | $415.25 |
| 36415 | Collection of venous blood by venipuncture | <1% | 298 | $400.63 |
| 0301 | <1% | 12 | $398.46 | |
| 29130 | <1% | 52 | $386.04 | |
| 73502 | <1% | 13 | $385.81 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 74 | $345.36 |
| 73590 | <1% | 13 | $321.63 | |
| 81003 | <1% | 82 | $272.80 | |
| 87210 | <1% | 40 | $247.42 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 84 | $244.38 |
| 81000 | <1% | 43 | $206.03 | |
| 87077 | <1% | 24 | $179.88 | |
| 84100 | <1% | 29 | $165.85 | |
| 82553 | <1% | 15 | $165.64 | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 16 | $140.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 43 | $133.48 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 28 | $92.17 |
| J2704 | Injection, propofol, 10 mg | <1% | 296 | $84.35 |
| 86140 | <1% | 14 | $81.13 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 15 | $68.02 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 258 | $57.98 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 12 | $27.28 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 125 | $17.62 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOAN, CHRISTOPHER (CHIEF COMPLINANCE COUNSEL)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.